The new Alzheimer’s drug that could break Medicare

Posted on AllSides June 10th, 2021
From The Left
Healthcare, Alzheimer's, Medicare
ANALYSIS

Patients are desperate for hope. But there are serious concerns about Biogen’s new $56,000 treatment.

Medicare, the federal health insurance program that covers Americans over 65, is facing an impossible dilemma: Should it cover a new and expensive medication for Alzheimer’s disease, which afflicts 6 million Americans and for which there is no existing treatment, even though the drug might not actually work?

It is an enormous question. Alzheimer’s patients and other families with members who endure mild cognitive impairment that may progress to Alzheimer’s have been waiting decades for an...

Read full story

Vox

AllSides Media Bias Rating: Left
AllSides Media Bias Rating: Left
106252/83948
See full bias rating for Vox
Learn about media bias
https://www.vox.com/policy-and-politics/22524608/new-alzheimers-drug-cost-fda-approval-biogen

More News about Healthcare from the Left, Center and Right

From the Left

From the Center

From the Right